The Debate on the Ethics of AI in Health Care: a Reconstruction and Critical Review

Jessica Morley1,2*, Caio C. V. Machado1*, Christopher Burr1, Josh Cowls1,2, Indra Joshi, Mariarosaria Taddeo1,2,3, Luciano Floridi1,2,3

1Oxford Internet Institute, University of Oxford, 1 St Giles’, Oxford, OX1 3JS, UK
2Alan Turing Institute, British Library, 96 Euston Rd, London NW1 2DB, UK
3Department of Computer Science, University of Oxford, 15 Parks Rd, Oxford, OX1 3QD, UK
* These authors contributed equally to the writing of this paper
** Email of correspondence author: Jessica.morley@kellogg.ox.ac.uk

Abstract

Healthcare systems across the globe are struggling with increasing costs and worsening outcomes. This presents those responsible for overseeing healthcare with a challenge. Increasingly, policymakers, politicians, clinical entrepreneurs and computer and data scientists argue that a key part of the solution will be ‘Artificial Intelligence’ (AI) – particularly Machine Learning (ML). This argument stems not from the belief that all healthcare needs will soon be taken care of by “robot doctors.” Instead, it is an argument that rests on the classic counterfactual definition of AI as an umbrella term for a range of techniques that can be used to make machines complete tasks in a way that would be considered intelligent were they to be completed by a human. Automation of this nature could offer great opportunities for the improvement of healthcare services and ultimately patients’ health by significantly improving human clinical capabilities in diagnosis, drug discovery, epidemiology, personalised medicine, and operational efficiency. However, if these AI solutions are to be embedded in clinical practice, then at least three issues need to be considered: the technical possibilities and limitations; the ethical, regulatory and legal framework; and the governance framework. In this article, we report on the results of a systematic analysis designed to provide a clear overview of the second of these elements: the ethical, regulatory and legal framework. We find that ethical issues arise at six levels of abstraction (individual, interpersonal, group, institutional, sectoral, and societal) and can be categorised as epistemic, normative, or overarching. We conclude by stressing how important it is that the ethical challenges raised by implementing AI in healthcare settings are tackled proactively rather than reactively and map the key considerations for policymakers to each of the ethical concerns highlighted.

Keywords
Artificial Intelligence; Ethics; Healthcare; Health Policies; Machine Learning.
1. Introduction

Healthcare systems across the globe are struggling with increasing costs and worsening outcomes (Topol, 2019). This presents those responsible for overseeing healthcare systems with a ‘wicked problem’, meaning that the problem has multiple causes, is hard to understand and define, and hence will have to be tackled from multiple different angles. Against this background, policymakers, politicians, clinical entrepreneurs and computer and data scientists increasingly argue that a key part of the solution will be ‘Artificial Intelligence’ (AI), particularly Machine Learning (Chin-Yee & Upshur, 2019). The argument stems not from the belief that all healthcare needs will soon be taken care of by “robot doctors” (Chin-Yee & Upshur, 2019). Instead, the argument rests on the classic counterfactual definition of AI as an umbrella term for a range of techniques (summarised in Figure 1 below) that can be used to make machines complete tasks in a way that would be considered intelligent were they to be completed by a human. For example, as mapped by (Harerimana, Jang, Kim, & Park, 2018), decision tree techniques can be used to diagnose breast cancer tumours (Kuo, Chang, Chen, & Lee, 2001); Support Vector Machine techniques can be used to classify genes (Brown et al., 2000) and diagnose Diabetes Mellitus (Barakat, Bradley, & Barakat, 2010); ensemble learning methods can predict outcomes for cancer patients (Kourou, Exarchos, Exarchos, Karamouzis, & Fotiadis, 2015); and neural networks can be used to recognise human movement (Jiang & Yin, 2015). From this perspective, AI represents a growing resource of interactive, autonomous, and often self-learning (in the machine learning sense, see Figure 1) agency, that can be used on demand (Floridi, 2019), presenting the opportunity for potentially transformative cooperation between machines and doctors (Bartoletti, 2019).

\[^1\] For a full overview of all supervised and unsupervised Machine Learning techniques and their applications in healthcare, see Harerimana, Jang, Kim, & Park, 2018 and for a detailed look at the number of papers related to AI techniques and their clinical applications see (Tran et al., 2019)
If harnessed effectively, such AI-clinician coordination (AI-Health) could offer great opportunities for the improvement of healthcare services and ultimately patients’ health (Taddeo & Floridi, 2018) by significantly improving human clinical capabilities in diagnosis (Arieno, Chan, & Destounis, 2019; De Fauw et al., 2018; Kunapuli et al., 2018), drug discovery (Álvarez-Machancoses & Fernández-Martínez, 2019; Fleming, 2018), epidemiology (Hay, George, Moyes, & Brownstein, 2013), personalised medicine (Barton et al., 2019; Cowie, Calveley, Bowers, & Bowers, 2018; Dudley, Listgarten, Stegle, Brenner, & Parts, 2015) or operational efficiency (H. Lu & Wang, 2019; Nelson, Herron, Rees, & Nachev, 2019). However, as Ngiam & Khor (2019) stress, if these AI solutions are to be embedded in clinical practice, then at least three issues need to be considered: the technical possibilities and limitations; the ethical, regulatory and legal framework; and the governance framework.

The task of the following pages is to focus on the second of these elements — the ethical, regulatory and legal framework — by stressing how important it is that the ethical challenges raised by
implementing AI in healthcare settings are tackled proactively (Char, Shah, & Magnus, 2018). If they are not, there is a risk of incurring significant opportunity costs (Cookson, 2018) due to what Floridi terms a ‘double bottleneck’ whereby “a double bottleneck: ethical mistakes or misunderstandings may lead to social rejection and/or distorted legislation and policies, which in turn may cripple the acceptance and advancement of [the necessary] data science”. Although essential, encouraging this kind of proactive ethical analysis is challenging because – although bioethical principles for clinical research and healthcare are well established, and issues related to privacy, effectiveness, accessibility and utility are clear (Nebeker, Torous, & Bartlett Ellis, 2019) – other issues are less obvious (Char et al., 2018). For example, AI processes may lack transparency, making accountability problematic, or may be biased, and leading to unfair behaviour or mistaken decisions (Mittelstadt, Allo, Taddeo, Wachter, & Floridi, 2016). Identification of these less obvious concerns requires input from the medical sciences, economics, computer sciences, social sciences, law, and policy-making. Yet, research in these areas is currently happening in siloes, is overly focused on individual level impacts (Morley & Floridi, 2019b), or does not consider the fact that the ethical concerns may vary depending on the stage of the algorithm development pipeline (Morley, Floridi, Kinsey, & Elhalal, 2019). Taken together, these issues are inhibiting the development of a coherent ethical framework.

Whilst AI-Health remains in the early stages of development and relatively far away from having a major impact on frontline clinical care (Panch, Mattie, & Celi, 2019) there is still time to develop this framework. However, this window of opportunity is closing fast, as the pace at which AI-Health solutions are gaining approval for use in clinical care in the US is accelerating (Topol, 2019). Both the Chinese (Zhang, Wang, Li, Zhao, & Zhan, 2018) and British governments (Department of Health and Social Care, 2019) have made it very clear that they intend on investing heavily in the spread and adoption of AI-Health technologies. It is for these reasons that the goal of this article is to offer a cross-disciplinary systematic review mapping the potential ethical implications of the development of AI-Health in order to support the development of better design practices, and transparent and accountable deployment strategies. We will do this in terms of digital ethics. That is, we will focus on the evaluation of moral problems related to data, algorithms and corresponding practices (Floridi & Taddeo, 2016), with the hope of enabling governments and healthcare systems looking to adopt AI-Health to be ethically mindful (Floridi, 2019a).

2 https://digitalethicslab.oii.ox.ac.uk/the-ethics-of-medical-data-analytics-opportunities-and-challenges/
2. Methodology in Brief

A detailed outline of the methodology used to conduct the review can be found in the appendix. For now, suffice to say that a traditional thematic review methodology (following Abdul, Vermeulen, Wang, Lim, & Kankanhalli, 2018) was used to find literature from across disciplinary boundaries that highlighted ethical issues unique to the use of AI algorithms in healthcare. This means that the review did not focus on issues such as lack of evidence, privacy and security (Vayena, Tobias, Afua, & Allesandro, 2018), or definitions and secondary uses of healthcare data, as these are ethical issues for digital health at large and not unique to AI. More detailed discussion of these issues is highlighted in Table 1.

<table>
<thead>
<tr>
<th>General Digital Health Ethical Concern</th>
<th>Example References</th>
</tr>
</thead>
<tbody>
<tr>
<td>Embodied Intelligence/Robotics</td>
<td>(Fiske, Henningsson, &amp; Buys, 2019)</td>
</tr>
<tr>
<td>Digital Divide/eHealth Literacy</td>
<td>(Celi et al., 2016) (Kuek &amp; Hakkennes, 2019)</td>
</tr>
<tr>
<td>Patient involvement</td>
<td>(Aitken et al., 2019) (Page, Manhas, &amp; Mruuve, 2016)</td>
</tr>
<tr>
<td>Patient Safety</td>
<td>(Barras, 2019)</td>
</tr>
<tr>
<td>Evidence of Efficacy</td>
<td>(Ferretti, Ronchi, &amp; Vayena, 2019) (Henson, David, Albright, &amp; Torous, 2019) (Larsen et al., 2019)</td>
</tr>
</tbody>
</table>

Table 1: Example literature related to ethical concerns that are relevant for all digital health intervention, not unique to AI-Health and therefore not included in this review.

To ensure that the focus stayed on the unique ethical issues, the map, developed by (Mittelstadt et al., 2016), of the epistemic, normative, and overarching ethical concerns related to algorithms was used as a base. First, the selected literature was reviewed to identify healthcare examples of each of the
concerns highlighted in the original map, as shown in Table 2, and then reviewed more thoroughly to identify how the ethical issues may vary depending on whether the analysis was being conducted at: (i) individual, (ii) interpersonal, (iii) group (e.g. family or population), (iv) institutional, (v) sectoral, and/or (v) societal levels of abstraction (LoA)\(^3\) (Floridi, 2008). This helped the review avoid the narrow focus on individual-level impacts highlighted in the introduction. This approach is not intended to imply that there is no overlap between the levels.

<table>
<thead>
<tr>
<th>Ethical Concern</th>
<th>Explanation</th>
<th>Medical Example</th>
</tr>
</thead>
<tbody>
<tr>
<td>Epistemic concerns</td>
<td>Inconclusive Evidence</td>
<td>Algorithmic outcomes (e.g. classification) are probabilistic and not infallible. They are rarely sufficient to posit the existence of a causal relationship.</td>
</tr>
<tr>
<td></td>
<td>Inscrutable Evidence</td>
<td>Recipients of an algorithmic decision very rarely have full oversight of the data used to train or test an algorithm or the data points used to reach a specific decision.</td>
</tr>
<tr>
<td></td>
<td>Misguided Evidence</td>
<td>Algorithmic outcomes can only be as reliable (but also as neutral) as the data they are based on.</td>
</tr>
<tr>
<td>Normative Concerns</td>
<td>Unfair outcomes</td>
<td>An action can be found to having more of an impact (positive or negative) on one group of people</td>
</tr>
<tr>
<td></td>
<td>Transformative effects</td>
<td>Algorithmic activities, like profiling, re-conceptualise reality in unexpected ways.</td>
</tr>
<tr>
<td>Overarching</td>
<td>Traceability</td>
<td>Harm caused by algorithmic activity is hard to debug (to detect the harm and find its cause), and it is hard to identify who should be held responsible for the harm caused.</td>
</tr>
</tbody>
</table>


\(^3\) A level of abstraction can be imagined as an interface that enables one to observe some aspects of a system analysed, while making other aspects opaque or indeed invisible. For example, one may analyse a house at the LoA of a buyer, of an architect, of a city planner, of a plumber, and so on. LoAs are common in computer science, where systems are described at different LoAs (computational, hardware, user-centred etc.). Note that LoAs can be combined in more complex sets, and can be, but are not necessarily hierarchical, with higher or lower ‘resolution’ or granularity of information.
3. Thematic Analysis
What follows is a detailed discussion of the issues uncovered. A summary table (Table 3) is provided at the end of the section.

3.1. Epistemic Concerns: Inconclusive, Inscrutable, and Misguided Evidence
Many factors are encouraging the development of AI-Health (Chin-Yee & Upshur, 2019). One of the main driving forces is the belief that algorithms can make more objective, robust and evidence-based clinical decisions (in terms of diagnosis, prognosis or treatment recommendations) than a human health care provider (HCP) can (Kalmady et al., 2019). This is not an unfounded position. Machine learning methods, especially ensemble and unsupervised methods (Harerimana et al., 2018), can take into account a far greater range of evidence (data) than a Health Care Provider (HCP) when making a clinical decision, including five of the seven dimensions of healthcare data provided by the US Department of Health and Human services: (1) demographic and socioeconomic data; (2) symptom and existing diagnosis data; (3) treatment data; (4) outcome data; and (5) other omic data (Holzinger et al., 2019). If designed taking into account the multiple epistemic concerns, this ability enables clinical algorithms to act as digital companions (Morley & Floridi, 2019d), reducing the information asymmetry that exists between a HCP and the individual seeking care by making available information accessible to both parties and helping ensure that the most informed decision possible is made by the person who has the right to make it (Morley & Floridi, 2019a).

It is at least in part due to this ability to make ‘evidence-based’ decisions that, as AI-health research has shown, AI techniques can considerably augment or surpass human capabilities when it comes to tasks including: (1) analysis of risk factors (De Langavant, Bayen, & Yaffe, 2018; Deng, Luo, & Wang, 2018); (2) prediction of disease (Moscoso et al., 2019); (3) prediction of infection (Barton et al., 2019)(López-Martínez, Núñez-Valdez, Lorduy Gomez, & García-Díaz, 2019); (4) population health monitoring (F. S. Lu, Hattab, Clemente, Biggerstaff, & Santillana, 2019; Zacher & Czogiel, 2019); (5) prediction of adverse effects (Ding, Tang, & Guo, 2019; Mortazavi et al., 2017); (6) prediction of outcome and/or likelihood of survival (Dong et al., 2019; Popkes et al., 2019; Topuz, Zengul, Dag, Almehmi, & Yildirim, 2018); and (7) analysing electronic health records (Shickel, Tighe, Bihorac, & Rashidi, 2018). These capabilities should not be underestimated, particularly as AI-Health solutions can operate at scale, diagnosing or predicting outcomes for multiple people at once –

4 The other two categories refer to data from the Healthcare system, such as expenditure and healthcare resources data.
something that an HCP could never do. Yet in many ways this almost unwavering faith in the truth-telling power of AI-Health is flawed.

As has been highlighted multiple times in the wider ethical AI literature, the belief that algorithms are more objective than humans is a ‘carefully crafted myth’ (Gillespie, Boczkowski, & Foot, 2014), and just because an algorithm can recognise a pattern (for example) does not necessarily make it meaningful (Floridi, 2014). In the context of healthcare, existing methods and studies (potentially including those referenced) suffer from overfitting due to small numbers of samples, meaning that the majority of results (e.g. patterns of disease risk factors, or presence of disease) are inconclusive (Holzinger et al., 2019). This is a problem that is further magnified by the lack of reproducibility, and external validity, of results. AI-Health solutions are often untranslatable between different settings and rarely work in settings different to those in which the initial result was obtained (Vollmer, Mateen, Bohner, Király, Ghani, et al., 2018), raising serious questions about the scientific rigor of AI-Health and its safety (Vayena, Blasimme, & Cohen, 2018). Furthermore, the results can often be heavily value-laden, based on the definition of ‘healthy’ by influential people or powerful companies (McLaughlin, 2016). This raises a number of significant ethical concerns.

At the individual LoA there is considerable risk of misdiagnosis. This can happen in at least two ways: either, as highlighted in table 2, by an individual using a wearable device that has a bug, or is inappropriately calibrated for them could be ‘told’ that they are suffering from a health condition when they are not (or vice versa) or, an HCP relying on clinical decision support software (CDSS) (Ruckenstein & Schüll, 2017) could be given an inaccurate diagnosis or recommendation which they do not question due to a tendency to uncritically accept the decisions of automated systems (Challen et al., 2019). Moreover, this can have impacts in medical practice, causing overreliance on the machine diagnostics and deskilling of practitioners (Cabitza, Rasoini, & Gensini, 2017). Not only is this a risk for individuals, but it also reverses the advantage of AI-Health solutions being able to operate at scale by introducing the group LoA ethical concern of misdiagnosis or missed diagnosis happening repeatedly. Whilst an HCP might give one person the wrong diagnosis and then be corrected, a faulty algorithm, based on the misguided, inscrutable or inconclusive evidence could give the same wrong diagnosis to hundreds or thousands of people at a time (Topol, 2019). The scale of the problems is as large as the scale of the solutions.

Building on this, there are also ethical implications at the interpersonal LoA. HCP-patient relationships are primarily based on trust and empathy, and whilst AI-Health solutions can take over tasks that are more routine and standardised, they cannot reproduce the emotional virtues of which human HCPs are capable (Ngiam & Khor, 2019). Consequently, an over-reliance on the ‘quantitative’
and objective evidence that fuels clinical algorithms (Cabitza et al., 2017) could discredit other forms of diagnosis (Rosenfeld et al., 2019) – a prominent concern in the case of clinical psychiatry (Burns, 2015) – and lead to the de-humanisation or impersonalisation of care provision (Juengst, McGowan, Fishman, & Settersten, 2016), from a service based on listening and theory to one based purely on categorisation (an issue that could again lead to a group LoA harm of group-profiling and associated discrimination by providers including insurers, see section 3.2.). Not only is this effectively ‘paternalism in disguise’ (Juengst et al., 2016) but it could also lead to poorer health outcomes due to the lack of disconnect between pure medical evidence and actual behaviour change (Emanuel & Wachter, 2019).

Finally, scaling up to the institutional, sectoral and societal LoAs, there is the concern that public health decisions are increasingly made on predictive AI-Health algorithms, which too often rely on the same flawed assumptions as outlined above. Regarding these assumptions, consider what is by now a classic example: the Google Flu Trends monitoring of the influenza virus. The initial algorithm distorted the spread of the virus in the US (Vayena, Salathé, Madoff, & Brownstein, 2015). If policy decisions about where to deploy health resources are based on such poor-quality evidence, this could result in the waste of public funds (e.g., promoting vaccination campaigns where they are not needed), damage local economies (e.g., scaring away tourists from a region) – which would result in a positive feedback loop of less money available for public expenditure – and lead to poorer quality public healthcare provision and thus worse health outcomes for society at large. This worry is particularly paramount when it is considered that the ultimate ambition of AI-Health is to create a learning healthcare system where the ‘system’ is constantly learning from the data it receives on the performance of its interventions (Faden et al., 2013). Furthermore, it is worth noting that, at this juncture, the example offered above of Flu Trends does not represent the limits of Google’s interest – and that of its subsidiaries and its siblings under parent company Alphabet – in public health. As we discuss below, the engagement between Alphabet’s artificial intelligence subsidiary DeepMind and a major UK hospital has attracted the attention of data protection regulators, the press, and academics (Information Commissioner, 2018; Powles & Hodson, 2017). The challenge of ensuring that AI-Health systems function accurately has in turn sparked debates about the appropriateness of sharing data between public and private entities. In response to claims that patient data transferred from the Royal Free Hospital to DeepMind was “far in excess of the requirements of those publicly stated needs” (Powles & Hodson, 2017), DeepMind representatives argued that “data processed in the application have been defined by and are currently being used by clinicians for the direct monitoring
and care of AKI [acute kidney injury] patients” (King et al., 2018). Powles and Hodson responded in turn that it is a “statement of fact that the data transferred is broader than the requirements of AKI” (Powles & Hodson, 2018). As this series of claims and counter-claims demonstrates, the quality and quantity of data required for a particular AI-Health application is likely to be a matter of dispute in the context of the collection and sharing of patient data in training AI-Health.

Ultimately, data is necessary for medical practice and thus so are AI-Health solutions that can take in greater volumes of data. But data collected and used in this way is insufficient to inform medical practice; it must be transformed to be useful (Car, Sheikh, Wicks, & Williams, 2019) and if this transformation process is flawed the results could be hugely damaging, resulting in either wasted funds and poorer health provision, or undue sharing of patient data with private sector actors under the guise of AI-Health.

3.2. Normative Concerns: Unfair Outcomes and Transformative Effects

As referenced in the introduction, healthcare systems across the globe are struggling with increasing costs and decreasing outcomes (Topol, 2019) and their administrators increasingly believe that the answer may well lie in making healthcare systems more informationally mature and able to capitalise on the opportunities presented by AI-Health significantly to improve outcomes for patients, and to reduce the burdens on the system (Cath, Wachter, Mittelstadt, Taddeo, & Floridi, 2017). Whilst it would be ethically remiss to ignore these opportunities (Floridi, 2019a), it would be equally ethically problematic to ignore the fact that these opportunities are not created by AI-Health technologies per se but by their ability to re-ontologise (that is, fundamentally transform the intrinsic nature of) the ways in which health care is delivered by coupling, re-coupling and de-coupling different parts of the system (Floridi, 2017a). For example (Morley & Floridi, 2019b):

- **Coupling**: patients and their data are so strictly and interchangeably linked that the patients are their genetic profiles, latest blood results, personal information, allergies etc. (Floridi, 2017a). What the legislation calls ‘data subjects” become “data patients”;
- **Re-Coupling**: research and practice have been sharply divided since the publication of the National Commission for the Protection of Human Subjects in the 1970s, but in the digital scenario described above, they are re-joined as one and the same again (Petrini, 2015) (Faden et al., 2013);
- **De-Coupling**: presence of Health Care Provider (HCP) and location of Patient become independent, for example because of the introduction of online consultations (NHS England, 2019).
As a result of these transformations a number of ethical concerns arise.

Starting once again with the individual LoA: as more diagnostic and therapeutic interventions become based on AI-Health solutions, individuals may be encouraged to share more and more personal data about themselves (Racine et al., 2019) — data that can then be used in opaque ways (Sterckx et al., 2016). This means that the ability for individuals to be meaningfully involved in shared decision making is considerably undermined (Vayena et al., 2018) As a result, the increasing use of algorithmic decision-making in clinical settings can have negative implications for individual autonomy, as for an individual to be able to exert agency over the AI-Health derived clinical decision, they would need to have a good understanding of the underlying data, processes and technical possibilities that were involved in it being reached (DuFault & Schouten, 2018) and be able to ensure their own values are taken into consideration (McDougall, 2019). The vast majority of the population do not have the level of eHealth literacy necessary for this (Kim & Xie, 2017), and those that do (including HCPs) are prevented from gaining this understanding due to the black-box nature of AI-Health algorithms (Watson et al., 2019). In extreme instances, this could undermine an individual’s confidence in their ability to refuse treatment (Thomas Ploug & Holm, 2019). Such issues pose a substantial threat to an individual’s integrity of self (the ability of an individual to understand the forces acting on them) (Cheney-Lippold, 2017). Given that damage to a person’s psychological integrity can be perceived as a ‘harm’, not accounting for this potentiality poses the risk of creating a system that violates the first principle of medical ethics: primum non nocere (“first, do no harm”) (Andorno, 2004; Morley & Floridi, 2019d).

It is not necessarily the case that harmful impacts will primarily be felt by the patients. At the interpersonal LoA, HCPs may themselves feel increasingly left ‘out of the loop’ as decisions are made by patients and their ‘clinical advice’ algorithm in a closed digital loop (Nag, Pandey, Oh, & Jain, 2017). As a result, HCPs may too feel unable to exert their own agency over the decision-making capacity of AI-Health solutions. Though the use of algorithmic decision-making makes diagnostics seem like a straightforward activity of identifying symptoms and fitting them into textbook categories, medical practice is much less clear-cut than it seems (Cabitza et al., 2017). Clinical practice involves a series of evaluations, trial and error, and a dynamic interaction with the patient and the medical literature. As a result, formal treatment protocols should be seen more as evaluative guidelines than well-defined, isolated categories. AI-Health solutions may not be in accordance with current best practice, which is
necessary to handle the great degree of uncertainty and can only be fully evaluated by physicians (Cabitza et al., 2017). Therefore, AI-Health solutions need to allow HCPs to exert influence in the decision-making process.

At the group LoA the concern is that AI-Health systems may well be able to cope better with illnesses and injuries that have well-established and fairly set (and therefore automatable) treatment protocols. These are more likely to exist for afflictions most commonly suffered by white men as there is a greater volume of medical trials data for this group than there is for almost any other group. Algorithms trained on such biased datasets could make considerably poorer predictions for, for example, younger black women (Vayena et al., 2018). If HCPs are left out of the loop completely and learning healthcare systems primarily rely on automated decisions, there is considerable potential to exacerbate existing inequalities between the “haves” and the “have-nots” of the digital healthcare ecosystem, i.e., those that generate enough data on themselves to ensure accurately trained algorithms and those that do not (Topol, 2019).

To mitigate these and associated risks, institutions need to be asking the crucial question: how much clinical decision-making should we be delegating to AI-Health solutions (Di Nucci, 2019)? If it is known that algorithms which enable profiling (e.g. those that determine genetic risk profiles) can ignore outliers and provide the basis for discrimination (Garattini et al., 2019), so deciding whether healthcare also ought to be a means to promote social justice is crucial in order to establish what type of data services will be embedded in the system (Voigt, 2019), what data should be collected, and which values should be embedded in algorithmic decision-making services (McDougall, 2019). This decision also determines what sort of population-level behavioural change the health system should be able to aim for depending on cost management, data collection and fairness in data-driven systems (Department of Health and Social Care, 2018). If not carefully considered, this process of transforming the provision of care risks over-fitting the system to a specific set of values that may not represent those of society at large (McDougall, 2019).

Another, more subtle yet pervasive transformative effect arises at the sectoral level. Powles & Hodson (2017) argue that one risk that may arise from collaboration between public and private sector entities such as that between the Royal Free London hospital and DeepMind is that the positive

---

5 Here we are discussing fairly routine illnesses and injuries that have set treatment protocols that may need to be flexibly interpreted on a case-by-case basis. We recognize that there are other instances, such as in the case of rare diseases, where algorithmic systems might be better equipped to deal with diagnostic uncertainty (for example in cases of rare diseases) by being able to draw on a wider range of data points and information sources than a human clinician could.
benefits of AI-Health “solutions” will be siloed within private entities. They note that in the Royal Free case, “DeepMind [was given] a lead advantage in developing new algorithmic tools on otherwise privately-held, but publicly-generated datasets” (Powles & Hodson, 2017, p. 362). This, they suggest, may mean that the only feasible way that future advances may be developed is “via DeepMind on DeepMind’s terms”. This interpretation was contested by DeepMind, who called it “unevidenced and untrue” and claimed that the Information Commissioner agreed with their stance in her 2018 ruling (King et al., 2018). Whatever the circumstances of this particular case, the broader risk of privately held AI-Health solutions – trained on datasets that have been generated about the public by public actors but then (lawfully) shared with private companies – is worthy of caution going forward.

As may now be clear, these transformative effects also have significant ethical implications at the societal LoA. Before institutions can establish where and how (and, from the sectoral perspective, whether) AI-Health solutions can improve care, society itself must make difficult decisions about what care is and what constitutes good care (Coeckelberg, 2014). To offer a simplistic example, does it mean purely providing a technical diagnosis and an appropriate prescription or does it involve contemplating a series of human necessities that revolve around well-being (Burr, Taddeo, & Floridi, 2019)? If it is the former, then it is relatively easy to automate the role of non-surgical clinicians through AI (although this does not imply that doctors should be substituted by AI systems). However, if it is the latter, then providing good health care means encompassing psychological wellbeing and other elements related to quality of life, which would make human interaction an essential part of healthcare provision, as a machine does not have the capability to make emotionally-driven decisions. Consequently, certain decisions may completely exceed the machine’s capabilities and thus delegating these tasks to AI-Health would be ethically concerning (Matthias, 2015).

Consider, for example, a situation where an AI-Health solution decides which patients are sent to the Intensive Care Unit (ICU). Intensive care is a limited resource and only people who are at risk of losing their lives or suffering grave harms are sent there. Triage decisions are currently made by humans with the aim of maximising well-being for the greatest number of people. Doctors weigh different factors when making this decision, including the likelihood of people surviving if they are sent to the ICU. These situations often involve practitioners (implicitly) taking moral stances, by prioritising individuals based on their age or health conditions. These cases are fundamentally oriented by legal norms and medical deontology, yet personal expertise, experience and values also inevitably play a role. Having the support of AI-Health in the ICU screening increases the number of agents and complicates the norms involved in these decisions, since the doctor may follow his or her professional guidelines, while the algorithm will be oriented by the values embedded in its code. Unless there is a
transparent process for society to be involved in the weighing of values embedded in these decision-making tools (for instance, how is ‘fair’ provision of care defined?) (Cohen, Amarasingham, Shah, Xie, & Lo, 2014), then the use of algorithms in such scenarios could result in the overfitting of the health system to a specific set of values that are not representative of society at large.

In response to this risk, some attempts have already been made to involve the public at large in decisions over the design and deployment of AI systems. In early 2019, the UK’s Information Commissioner’s Office and the National Institute for Health Research staged a series of “citizens’ juries” to obtain the opinions of a representative cross-section of British society regarding the use of AI in health (Information Commissioner, 2019). The “juries” were presented with four scenarios, two relating to health — using AI to diagnose strokes, and using it to find potential matches for a kidney transplant — and another two relating to criminal justice. Notably, the juries “strongly favoured accuracy over explanation” in the two scenarios involving AI in health (National Institute for Health Research, 2019). This is just one example of research which attempted to obtain public opinion data regarding AI in health, and there are reasons to suppose that the apparent preference among participants for accurate over explainable AI systems reflects the high-stakes and fast-moving scenarios that were presented (as opposed to, say, the more routine illnesses and injuries we are focusing on here). Nonetheless, it demonstrates the plausibility and preferability of involving the public in designing AI-Health systems.

To conclude this sub-section, the notion that AI-Health technologies are ethically neutral is unrealistic, and having them perform moral decision-making and enforcement may provoke immoral and unfair results (Rajkomar, Hardt, Howell, Corrado, & Chin, 2018). The direct involvement of the public in the design of AI-Health may help mitigate these risks. This should be borne in mind by all those involved in the AI-driven transformation of healthcare systems.

3.3 Overarching Concerns: Traceability

The previous sub-section outlined how the increasing use of AI-Health is fundamentally transforming the delivery of healthcare and the ethical implications of this process, particularly in terms of potentially unfair outcomes. This transformation process means that healthcare systems now rely on a dynamic, cyclical and intertwined series of interactions between human, artificial and hybrid agents (Vollmer, Mateen, Bohner, Király, & Ghani, 2018)(Turilli & Floridi, 2009). This is making it increasingly challenging identify interaction-emerging risks and allocate liability, raising ethical concerns with regards to moral responsibility.
Moral responsibility involves both looking forward, where an individual, group or organisation is perceived as being in charge of guaranteeing a desired outcome, and looking backwards to appropriate blame and possibly redress, when a failure has occurred (Wardrope, 2015). In a well-functioning healthcare system, this responsibility is distributed evenly and transparently across all nodes so that the causal chain of a given outcome can be easily replicated in the case of a positive outcome, or prevented from repeating in the case of a negative outcome (Floridi, 2013, 2016). In an algorithmically-driven healthcare system, a single AI diagnostic tool might involve many people organising, collecting and brokering data, and performing analyses on it, making this transparent allocation of responsibility almost impossible. In essence, not only is the decision-making process of a single algorithm a black-box, but the entire chain of actors that participate in the end product of AI-Health solutions is extremely complex. This makes the entire AI-Health ecosystem inaccessible and opaque, making responsibility and accountability difficult.

To unpack the ethical implications of this at-scale lack of traceability, let us take the example of a digital heart-rate monitor that ‘intelligently’ processes biological and environmental data to signal to its user their risk of developing a heart condition.

At the **individual LoA** this process relies on what can be termed the ‘digital medical gaze’ (Morley & Floridi, 2019d) and is based on this micro-cycle of self-reflection adapted from (Garcia, Romero, Keyson, & Havinga, 2014):

1. **Gaining Knowledge**: Algorithm reads multi-omic dataset to determine risk of heart attack and providers individual with a ‘heart health score’
2. **Gaining Awareness**: on the advice of the algorithm, individual starts monitoring their activity level and becomes aware of how active they are
3. **Self-reflection**: as directed by the algorithm the individual reflects on how much high fat food they are eating in a day and compares this to their optimal diet based on their genomic profile and their level of activity
4. **Action**: individual takes the advice of the algorithm and takes specific actions to improve their heart-health score e.g. starts regular exercise.

If this does not work, and the individual still ends up experiencing heart failure, this process of algorithmic surveillance (Rich & Miah, 2014) risk creating an elaborate mechanism for victim-blaming (Danis & Solomon, 2013; McLaughlin, 2016). The individual may be seen as being a ‘bad user’ for failing to act upon the allegedly objective and evidence-based advice of the algorithm (see section 3.1), and may therefore be framed as being morally responsible for their poor health and not deserving of state-provided healthcare. Yet, due to the lack of traceability, there can be no certainty that the poor
outcome was due to the lack of action by the individual: it could be a faulty device, buggy code, or the result of biased datasets (Topol, 2019). Moreover, even if a negative outcome were to result purely from an individual disregarding the guidance, the adoption of digital infrastructure that enables failure to be ascribed to a morally ‘culpable’ individual is itself a matter of ethical concern. These new insights may enable lives to be saved and quality of life to be drastically improved, yet they also shift the ethical burden of ‘living well’ squarely onto newly accountable individuals. The ontological shift that this new infrastructure permits — from individuals-as-patients deserving quality healthcare, regardless of their prior choices as fallible humans, to individuals-as-agents expected to take active steps to pre-empt negative outcomes — raises stark questions for bioethics, which has traditionally been seen as an “ethics of the receiver” (Floridi 2008). Moreover, these technological changes might prompt a shift in the ethical framework, burdening the individuals, while not providing de facto means of behavioural change. Many concerns stem from socio-demographic issues which entail harmful habits, and cannot oversimplified to a matter of delivering the adequate information to the patient (Owens & Cribb, 2019).

Due to issues of bias (discussed further in section 3.2), there is, further, a group LoA ethical risk that some groups may come to be seen as being more morally irresponsible about their healthcare than others. Heart-rate monitors, for example, are notoriously less accurate for those with darker skin (Hailu, 2019), meaning that they could give considerably less accurate advice to people of colour than to those with light skin. If this results in people of colour being less able to use AI-Health advice to improve their heart-health, then these groups of people may be seen as morally reprehensible when it comes to their health. Furthermore, the healthcare could then ‘learn’ to predict that people of colour have worse heart-health, potentially resulting in these groups of individuals being discriminated against by, for example, insurers (Martani, Shaw, & Elger, 2019).

At the interpersonal, institutional and sectoral LoAs, this moral responsibility translates into liability. If for example, instead of the heart-health algorithm providing the advice back to the individual, it provides the data to the individual’s HCP and the HCP provides advice that either fails to prevent an adverse event or directly causes an adverse event, this could be the basis of a medical malpractice suit (Price, 2018). In this scenario, it remains unclear where the liability will eventually sit (Ngiam & Khor, 2019). Current law implies that the HCP would be at fault, and therefore liable, for an adverse event as the algorithm in this scenario would be considered a diagnostic support tool – just like a blood test – with no decision making capacity, so it is the HCP’s responsibility to act appropriately based on the information provided (Price, Gerke, & Cohen, 2019; Schönberger, 2019; Sullivan & Schweikart, 2019). However, the supply chain for any clinical algorithm is considerably
more complex and less transparent than that of a more traditional diagnostic tool meaning that many are questioning whether this is actually how the law will be interpreted in the future. For example, does the liability really sit with the HCP for not questioning the results of the algorithm, even if they were not able to evaluate the quality of the diagnostic against other sources of information, including their own personal knowledge of the patient due to the black-box nature of the algorithm itself? And what about the role of the hospital or care facility: does it have a responsibility to put in place a policy allowing HCPs to overrule algorithmic advice when this seems indicated? Similarly, what role do commissioners or retailers of the device that contains the algorithm play? Do they not carry some responsibility for not checking its accuracy, or do they assume that this responsibility sits with the regulator (for example MHRA in the UK, the FDA in the US or the CFDA in China) who should, therefore, carry the burden for not appropriately assessing the product before it was deployed in the market? What if the problem is further back in the chain, stemming from inaccurate coding or poor-quality training data? There is a clear lack of distributed responsibility (Floridi, 2013, 2016)—a problem that is exacerbated by a lack of transparency—making it hard to hold individual parts of the chain accountable for poor outcomes which poses a significant ethical risk.

In their overview of patient-safety issues with AI in healthcare He et al. (2019) state that those working in the field are trying to establish a systems-wide approach that does not attribute blame to individuals or individual companies, but conclude that where liability will ultimately rest remains to be seen. This is problematic because, as Hoffman et al. (2019) stress, uptake of algorithmic-decision-making tools by the clinical community is highly unlikely until this liability question is resolved (Vayena et al., 2018), which could result in the overarching ethical concern raised in the introduction—that of a significant missed opportunity. Many, including (Holzinger et al., 2019) believe that explainability is the answer to solving this problem and that, if HCPs can understand how a decision was reached, then reflecting on the output of an algorithm is no different from any other diagnostic tool. Indeed Schönberger (2019) argues that legally this is the case and that as long as it can be proven that the duty of care was met, then harm caused to a patient by an erroneous prediction of an AI-Health system would not yet constitute medical negligence but that it might in the near future constitute negligence to not rely on the algorithmic output—which brings us back to the issues outlined in section 3.1.

Overall, this lack of clarity will continue to persist for some time (Schönberger, 2019), making it once again a social issue. Society will ultimately dictate what the socially acceptable and socially preferable (Floridi & Taddeo, 2016) answers are to these pressing questions. The ethical issue is whether all parts of society will have an equal say in this debate, as in the example of citizens’ juries above, or whether it will be those individuals or groups with the loudest voices that get to set the rules.
As (Beer, 2017) attests, when thinking about the power of an algorithm, we need to think beyond the impact and consequences of the code, to the powerful ways in which notions and ideas about the algorithm circulate throughout the social world.

<table>
<thead>
<tr>
<th>A. Individual</th>
<th>B. Interpersonal</th>
<th>C. Group</th>
<th>D. Institutional</th>
<th>E. Sectoral</th>
<th>F. Societal</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Epistemic concern (inconclusive, inscrutable and misguided evidence)</td>
<td>Misdiagnosis or missed diagnosis</td>
<td>Loss of trust in HCP-Patient relationships, de-personalisation of care</td>
<td>Misdiagnosis or missed diagnosis at scale – some groups more affected than others</td>
<td>Waste of funds and resources not directed to areas of greater need</td>
<td>Excessively broad data sharing between public and private entities</td>
</tr>
<tr>
<td>2. Normative (transformative effects and unfair outcomes)</td>
<td>Surveillance &amp; undermining of autonomy and integrity of self</td>
<td>Deskilling of HCPs, overreliance on AI tools, and undermining of consent practices and redefining roles in the healthcare system</td>
<td>Profiling and discrimination against certain groups seen as being less healthy or higher risk</td>
<td>Transformation of care pathways &amp; imposing of specific values at scale – redefining ‘good care’</td>
<td>Silencing of new AI tool development within private sector</td>
</tr>
<tr>
<td>3. Overarching (traceability)</td>
<td>‘Bad Users’ could come to be blamed for their own ill-health</td>
<td>See institutional</td>
<td>Specific groups framed as being more morally irresponsible with regards to their health than others</td>
<td>Lack of clarity over liability with regards to issues with safety and effectiveness could halt adoption or result in certain groups being blamed more often than others</td>
<td>See institutional</td>
</tr>
</tbody>
</table>

Table 3: summary of the epistemic, normative and overarching ethical concerns associated with AI-Health at the five different LoAs as identified by the literature review

4. The Need for an Ethically-Mindful and Proportionate Approach

The literature surveyed in this review clearly indicates the need for an agreed pro-ethical blueprint for AI-Health that considers the epistemic, normative and traceability ethical concerns at the five different LoAs. Protecting people from the harms of AI-Health goes beyond protecting data collection and applying a valid model. Normative frameworks need to contemplate the complexities of the human interactions where these technologies will be introduced and their emotional impacts (Luxton, 2014; Rick, 2016).

Importantantly, an adequate normative framework should deal with the key question related to liability allocation in cases of medical error. Much of the risk of handling data and algorithms stems from professionals not adopting measures to protect privacy and support cybersecurity. The solution of risk management will come not only from drawing the boundaries of responsibility, but also
promoting capacitation, understanding and interfaces for handling AI tools. For one, promoting doctors’ and patients’ understanding and control over how AI-health produces predictions or recommendations that are used in treatment plans, and access to and protection of patient data (Ngiam & Khor, 2019). Also, there needs to be control over how the interface and design of AI-health products influence HCP-patient-artificial-agent interactions (Cohen et al., 2014). Finally, a certification for professionals seeking to use AI-health tools is also necessary for the adequate implementation and use of AI (Kluge, Lacroix, & Ruotsalainen, 2018).

To tackle these challenges, healthcare systems will need to update outdated governance mechanisms (policies, standards and regulations). These can be replaced with both hard and soft mechanisms, meaning what ought to be done and what may be done based on the existing moral obligations (Floridi, 2018), that balance the need to protect individuals from harm, whilst still supporting innovation that can deliver genuine system and patient benefit (Morley & Joshi, 2019). In short, healthcare systems should not be overly cautious about the adoption of AI-health solutions, but should be mindful of the potential ethical impacts (Floridi, 2019a) so that proportionate governance models can be developed (Sethi & Laurie, 2013) which can, in turn, ensure that those responsible for ensuring that healthcare systems are held accountable for the delivery of high-quality equitable and safe care, can continue to be so.

What these regulations, standards and policies should cover and how they should be developed remain open questions (Floridi, 2017b) which will likely be ‘solved’ multiple times over by different healthcare systems operating in different settings. However, in order to lend a more systematic approach to addressing these outstanding questions, enabling greater coherence and speed in addressing these challenges, in Table 4 below we have assembled a list of essential cross-cutting considerations that emerge from our literature review. The table indicates from which aspect of our systematic review (ethical concern x LoA, corresponding to a cell in Table 3) each consideration is drawn.
<table>
<thead>
<tr>
<th>Consideration</th>
<th>Key supporting literature</th>
<th>Relevant aspects (ascending LoA)</th>
</tr>
</thead>
<tbody>
<tr>
<td>The professional skills required of the healthcare workforce, including information governance skills</td>
<td>(Kluge et al., 2018)</td>
<td>Epistemic (A, B, C, F) Normative (B, C, D, E) Overarching (A, C)</td>
</tr>
<tr>
<td>Which tasks should be delegated to AI-Health solutions</td>
<td>(Di Nucci, 2019)</td>
<td>Epistemic (A, B, C, D, F) Normative (B, C, D, F) Overarching (A, C, D)</td>
</tr>
<tr>
<td>What evidence is needed to ‘prove’ clinical effectiveness of an AI-Health solution</td>
<td>(Greaves et al., 2018)</td>
<td>Epistemic (A, B, C, E, F) Normative (E) Overarching (A, C, D, F)</td>
</tr>
<tr>
<td>Mechanisms for the inclusion of all relevant stakeholder views in the development of AI-Health systems</td>
<td>(Aitken et al., 2019)</td>
<td>Epistemic (C, E, F) Overarching (A, C, D, F)</td>
</tr>
<tr>
<td>Transparency over how algorithmic tools are integrated into the healthcare workflow, how it shapes decisions, and how it affects process optimization within medical services</td>
<td>(Effy Vayena et al., 2015)</td>
<td>Epistemic (A, B, C, D, E, F) Normative (A, B, D, E) Overarching (A, D, F)</td>
</tr>
<tr>
<td>How traditional and non-traditional sources of health data can be incorporated into AI-Health decision making, how it can be appropriately protected and how it can be harmonised</td>
<td>(e.g. Maher et al., 2019; Ploug &amp; Holm, 2016; Richardson, Milam, &amp; Chrysler, 2015; Townend, 2018)</td>
<td>Epistemic (A, C, D, E, F) Normative (A, C, D, E, F) Overarching (A, C, D)</td>
</tr>
<tr>
<td>How bioethical concepts (beneficence, non-maleficence, autonomy and justice (Beauchamp &amp; Childress, 2013) are challenged by AI-Health</td>
<td>(Mittelstadt, 2019)</td>
<td>Epistemic (B, F) Normative (A, C, D, F) Overarching (A, F)</td>
</tr>
<tr>
<td>How concepts such as fairness, accountability and transparency can be maintained at scale (Morley &amp; Floridi, 2019b) so that, for example, the output of algorithmic diagnostics does not result in economic benefits to specific drug producers or technology companies</td>
<td>(Rosenfeld et al., 2019)</td>
<td>Epistemic (C, D, E, F) Normative (D, E, F) Overarching (F)</td>
</tr>
</tbody>
</table>

Table 4: the 11 key considerations for policymakers that arose from the literature review.

Awareness of the need to consider these questions is increasing, and efforts are being made at both a national and international level to adapt existing regulations so that they remain fit for purpose.\(^6\)\(^{\text{The}}\)

\(^{6}\) Denoted by an increasing Level of Analysis: Individual (A), Interpersonal (B), Group (C), Institutional (D), Sectoral (E) and Societal (F).
Lancet Digital Health, 2019). The American Food and Drug Administration (FDA) is now planning on regulating Software as a Medical Devices (SaMD) (Food and Drug Administration (FDA), 2019) and in both the EU and the UK Regulation 2017/745 on medical devices comes into effect in April 2020 and significantly increases the range of software and non-medical products that will need to be classed (and assessed) as medical devices. Additionally, the UK has published its Code of Conduct for data-driven health and care technologies, standards for evidence of clinical effectiveness for digital health technologies (Greaves et al., 2018) – a digital assessment questionnaire standards for apps – and is currently developing a ‘regulation as a service’ model to ensure that there are appropriate regulatory checks at all stages of the AI development cycle (Morley & Joshi, 2019). The World Health Organisation has a number of projects under way to develop guidance for member states (Aicardi et al., 2016) (World Health Organisation, 2019). In China, several norms provide specific and detailed instructions to ensure health data security and confidentiality (Wang, 2019) to ensure that health and medical big data sets can be used as a national resource to develop algorithms (Zhang et al., 2018) for the improvement of public health (Li, Li, Jiang, & Lan, 2019).

These are all steps in the right direction, however, their development is progressing slowly (which is why the relevant literature is unlikely to reflect all current developments) and almost all focus solely on interventions positioning themselves as being health-related in the medical sense, not in the wider, wellbeing sense, e.g., healthy exercise, diet, sleeping habits). They will not necessarily mitigate risks are associated with the expanding wellness industry, which provides algorithmic tools that potentially enable people to bypass formal and well-regulated healthcare systems entirely by accessing technology directly, either by using a wearable device or consulting online databases (Burr et al., 2019). Similarly, although some technical solutions have been put forward for mitigating issues with data bias (Gebru et al., 2018; Holland, Hosny, Newman, Joseph, & Chmielinski, 2018) and data quality (Dai, Yoshigoe, & Parsley, 2018) and ensuring social inclusion in decision making (Balthazar et al., 2018; Friedman, Hendry, & Borning, 2017; Rahwan, 2018), these remain relatively untested. Unless a competitive advantage of taking such pro-ethical steps becomes clear without these approaches being made mandatory, it is unlikely that they will have a significant impact on the ethical impacts of AI-Health in the near future. As a result, there is still little control over the procedures followed and quality.

control mechanisms (Cohen et al., 2014) involved in the development, deployment and use of AI-Health.

As these comparatively easier to tackle problems do not yet have adequate solutions, it is unsurprising that the bigger issues regarding the protection of equality of care (Powell & Deetjen, 2019), fair distribution of benefits (Balthazar et al., 2018) (Kohli & Geis, 2018) and the protection and promotion of societal values (Mahomed, 2018) have barely even been considered. Given that healthcare systems in many ways act as the core of modern societies this is concerning. If mistakes are made too early in the adoption and implementation of AI in healthcare, the fall-out could be significant enough to undermine public trust, resulting in significant opportunity costs, and potentially encouraging individuals to seek their healthcare from outside of the formal systems where they may be presented with even greater risks. A coherent approach is needed and urgently, hopefully this systematic overview of the issues to be considered can help speed up its development.

5. Conclusion

This thematic literature review has sought to map out the ethical issues around the incorporation of data-driven AI technologies into healthcare provision and public health systems. In order to make this overview more useful, the relevant topics have been organised into themes and five different levels of abstraction (LoAs) have been highlighted. The hope is that by encouraging a discussion of the ethical implications of AI-Health at individual, interpersonal, group, institutional and societal LoAs, policymakers and regulators will be able to segment a large and complex conversation into tractable debates around specific issues, stakeholders, and solutions. This is important, as Topol (2019) states ‘there cannot be exceptionalism for AI in medicine,’ especially not when there is potentially so much to gain (Miotto, Wang, Wang, Jiang, & Dudley, 2018).

With this in mind, the review has covered a wide range of topics while also venturing into the specificity of certain fields. This approach has made it to develop a fuller and more nuanced understanding of the ethical concerns related to the introduction of AI into healthcare systems than has been previously seen in the literature. Inevitably, there are limitations to this approach, which are specified in the appendix, detailing our methodology and pointing towards opportunities for further research.

In this article, we hope to have provided a sufficiently comprehensive, detailed, and systematic analysis of the current debates on ethical issues related to the introduction of AI into healthcare systems. The aim is to help policymakers and legislators develop evidence-based and proportionate
policy and regulatory interventions. In particular, we hope to encourage the development of a system of transparent and distributed responsibility, where all those involved in the clinical algorithm supply chain can be held proportionately and appropriately accountable for the safety of the patient at the end, not just the HCP. It is only by ensuring such a system is developed that policymakers and legislators can be confident that the inherent risks we have described are appropriately mitigated (as far as possible) and only once this is the case will the medical community at large feel willing and able to adopt AI technologies.
Appendix – Methodology

The data collection for this research was divided into three stages as outlined in the below schematic.

This process resulted in approximately 147 papers suitable for analysis and inclusion in the initial review. Subsequent relevant papers that met the criteria were added at a later date during the writing up of the results.

This literature review also included accessory readings and case studies that were encountered during the research process. This includes bibliography obtained from the references of the papers analysed, and case studies identified in the readings (e.g. the Deep Mind case study). It is our belief that these exploratory readings enrich our systematic approach by developing on interesting findings and topics identified throughout our investigation.

It is important to note that the selection of articles and policy documents was restricted to those written in English. This means that some ethical issues will have been overlooked (e.g. those in Spanish-speaking countries or in China). Second, academic literature, much like regulation, tends to struggle to keep pace with technological development. This literature review did not seek to identify
ethical issues associated with specific use cases of AI first-hand, for example, by reviewing recently published studies available on pre-print servers such as arXiv, but instead focused on providing an overview of the ethical issues already identified. As a result, there may well be ethical concerns that are associated with more emergent use cases of AI for healthcare that we have not identified as they have not yet been discussed in formal peer-reviewed publications.

To overcome these limitations, further research could seek to expand the literature review by including a wider range of search queries, and by taking a case-study approach to analysing the ethical issues of specific practices and then aggregating these. This could be complemented by a comprehensive review of the policies, standards and regulations in development in different healthcare systems across the globe to assess the extent to which these are likely to be effective at mitigating these ethical concerns.

<table>
<thead>
<tr>
<th>Technology</th>
<th>Ethics/Concerns</th>
<th>Field</th>
</tr>
</thead>
<tbody>
<tr>
<td>Algorithm*</td>
<td>Fairness</td>
<td>Health*</td>
</tr>
<tr>
<td>Artificial Intelligence / AI</td>
<td>Moral*</td>
<td></td>
</tr>
<tr>
<td>Machine Learning</td>
<td>Ethics</td>
<td>Governance</td>
</tr>
</tbody>
</table>

Table 5: Showing terms refined from Mittelstadt et al (2016) and selected to focus the literature search on publications focusing specifically on the ethics of AI for health. It is important to note that the search parameters were not exactly the same in all databases. Adaptation was necessary since not all databases operated with the same syntax or accepted the same number of search queries. As a result, the arrangement of Boolean operators and a search parameter were adapted to ensure that all possible combinations were covered.

<table>
<thead>
<tr>
<th>Database</th>
<th>Search Query</th>
<th>Results</th>
<th>Titles Selected</th>
<th>Titles Downloaded</th>
</tr>
</thead>
<tbody>
<tr>
<td>SCOPUS</td>
<td>ethic* AND algorithm* AND health*</td>
<td>596</td>
<td>39</td>
<td>19</td>
</tr>
<tr>
<td></td>
<td>( ethic* AND (&quot;Artificial Intelligence&quot; OR ai ) AND health* )</td>
<td>239</td>
<td>37</td>
<td>15</td>
</tr>
<tr>
<td></td>
<td>( moral* AND (&quot;Artificial Intelligence&quot; OR ai ) AND health* )</td>
<td>46</td>
<td>2</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>( fair* AND (&quot;Artificial Intelligence&quot; OR ai ) AND health* )</td>
<td>122</td>
<td>6</td>
<td>3</td>
</tr>
<tr>
<td></td>
<td>(moral* OR ethic*) AND &quot;machine learning&quot; AND health*</td>
<td>91</td>
<td>14</td>
<td>9</td>
</tr>
<tr>
<td></td>
<td>(fair* ) AND &quot;machine learning&quot; AND health*</td>
<td>70</td>
<td>5</td>
<td>3</td>
</tr>
<tr>
<td>Web of Science</td>
<td>((fair* OR moral* OR ethic*) AND (&quot;machine learning&quot; OR &quot;Artificial Intelligence&quot; OR &quot;AI&quot; OR algorithm*) AND health*)</td>
<td>668</td>
<td>45</td>
<td>26</td>
</tr>
<tr>
<td>Philpapers</td>
<td>&quot;machine learning&quot; AND health*</td>
<td>3</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td></td>
<td>Artificial Intelligence AND health* AND ethic*</td>
<td>1000+</td>
<td>-</td>
<td>-</td>
</tr>
<tr>
<td></td>
<td>algorithm* AND health* AND ethic*</td>
<td>5</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td></td>
<td>ethics AND &quot;artificial intelligence&quot; AND health</td>
<td>3</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td></td>
<td>AI or Artificial Intelligence or Fair AND ethic or moral or health AND health*</td>
<td>9</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>Google Scholar</td>
<td>ethics algorithms health</td>
<td>15,400</td>
<td>18</td>
<td>18</td>
</tr>
<tr>
<td></td>
<td>ethics of machine learning in health</td>
<td>21,300</td>
<td>11</td>
<td>10</td>
</tr>
<tr>
<td></td>
<td>ETHICS &amp; HEALTH and at least one of: algorithm OR machine learning OR artificial intelligence OR AI</td>
<td>716,000</td>
<td>2</td>
<td>1</td>
</tr>
</tbody>
</table>
Table 6: Showing the final results from all searches. It is important to note that multiple search queries were made to cover all the combinations and the numbers in the table thus represent the sum of results, titles evaluated and downloaded (not all found files were accessible for download). It is also important to note that only the first 500 most relevant results from Google Scholar were reviewed and anything written before 2014 was excluded to make the number of results more manageable.

<table>
<thead>
<tr>
<th>Search Query</th>
<th>Results</th>
<th>Titles Evaluated</th>
<th>Downloads</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETHICS &amp; HEALTH and at least one of: algorithm OR AI</td>
<td>105,000</td>
<td>2</td>
<td>2</td>
</tr>
<tr>
<td>MORAL &amp; HEALTH and at least one of: algorithm OR AI</td>
<td>26,900</td>
<td>2</td>
<td>1</td>
</tr>
<tr>
<td>FAIR &amp; HEALTH and at least one of: algorithm OR AI</td>
<td>38,000</td>
<td>0</td>
<td>0</td>
</tr>
<tr>
<td>PubMed ETHICS &amp; ARTIFICIAL INTELLIGENCE OR MACHINE LEARNING</td>
<td>34,193</td>
<td>37</td>
<td>37</td>
</tr>
</tbody>
</table>

**Funding**

Taddeo and Floridi’s work was partially supported by Privacy and Trust Stream – Social lead of the PETRAS Internet of Things research hub – PETRAS is funded by the UK Engineering and Physical Sciences Research Council (EPSRC), grant agreement no. EP/N023013/1. Caio’s, Taddeo’s and Floridi’s work was also partially supported by a Microsoft grant and a Google grant.
References


29


Mann, S. P., Savulescu, J., & Sahakian, B. J. (2016). Facilitating the ethical use of health data for the benefit of society: Electronic health records, consent and the duty of easy rescue. *Philosophical Transactions of the


